Vertex Takes Early Lead In HCV Protease Inhibitor Sales
Incivek, launched in May, already has posted sales of $74.5 million, while Merck's competing Victrelis has tallied $21 million in sales so far.
Incivek, launched in May, already has posted sales of $74.5 million, while Merck's competing Victrelis has tallied $21 million in sales so far.